Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Janssen’s type 2 diabetes treatment is in a battle with rival drugs (especialy in its SGLT2 inhibitor class), where proof of cardiovascular benefits are now vital for future market share. ... The first SGLT2 inhibitor to gain this EU label update was

Latest news

  • J&J’s Invokana aces diabetic kidney disease trial, setting up filings J&J’s Invokana aces diabetic kidney disease trial, setting up filings

    Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted early – potentially opening up a lucrative new ... risk of lower-limb amputation in diabetics,

  • J&J says real-world data finds no amputation risk for Invokana J&J says real-world data finds no amputation risk for Invokana

    A year ago, regulators slapped warnings to the labelling for Johnson &Johnson’s diabetes drug Invokana, setting it at a disadvantage against rival drugs in the SGLT2 inhibitor class, but now ... results show that the “overall benefit-risk profile of

  • PMCPA takes AZ to task over asthma drug press release PMCPA takes AZ to task over asthma drug press release

    body. The source of GSK’s anger was a PR put out by AZ after interleukin-5 inhibitor Fasenra (benralizumab) was recommended for approval by the EMA’s Committee for Medicinal ... company in Amsterdam last November relating to SGLT2 inhibitor diabetes

  • FDA starts review of Sanofi’s oral type 1 diabetes drug FDA starts review of Sanofi’s oral type 1 diabetes drug

    The drug is a dual inhibitor of SGLT1 and SGLT2 and is thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... The SGLT2-selective drugs are approved to date only for type 2

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... Steglatro is the

More from news
Approximately 1 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics